子类别 期刊論文 [327/330] 圖書 [1/1] 會議論文/會議摘要 [115/179] 邻近社群 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張俊彥 [234/254] 張光裕 [69/79] 張憶壽 [103/106] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [66/71] 蘇勇曄 [40/40] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [464/471] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] 社群统计 近3年内发表的文件:74(14.51%) 含全文笔数:443(86.86%) 文件下载次数统计 下载大于0次:443(100.00%) 下载大于100次:425(95.94%) 全文下载总次数:177154(3.31%) 最后更新时间: 2024-11-28 16:05 上传排行 数据加载中..... 下载排行 数据加载中..... 最近上传 Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on... Chromatin remodeling-related PRDM1 ...

跳至: (选择年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (选择月份) January February March April May June July August September October November December 或输入年份:

由新到旧排序 由最旧的开始

显示项目376-400 / 510. (共21页) << < 11 12 13 14 15 16 17 18 19 20 > >> 每页显示[10|25|50]项目

日期	题名	關聯
2012-03	Involvement of autophagy in endogenous and NVP-AUY922-induced C-kit degradation in both imatinib-sensitive and -resistant gastrointestinal stromal tumor cells	Annals of Oncology. 2012 Mar;23(Suppl. 1):28.
2012-02	Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma	International Journal of Radiation Oncology, Biology, Physics. 2012 Feb;82(2):817-825.
2012-02	EGFR nuclear import in gallbladder carcinoma: Nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact	Annals of Surgical Oncology. 2012 Feb;19(2):443-454.
2012-02	Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on firstline oxaliplatin-based chemotherapy	Journal of Clinical Oncology. 2012 Feb;30(4):613.
2012-01	Long-term results of a randomized, observation-controlled, phase III trial of adjuvant Interferon alfa-2b in hepatocellular carcinoma after curative resection	Annals of Surgery. 2012 Jan;255(1):8-17.
2011-12-15	Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors	Free Radical Biology and Medicine. 2011 Dec 15;51(12):2195-2209.
2011-12	Induction chemotherapy with gemcitabine, oxaliplatin, and 5-Fluorouracil/Leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study	International Journal of Radiation Oncology, Biology, Physics. 2011 Dec;81(5):e749-e757.
2011-12	t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement	Cancer Chemotherapy and Pharmacology. 2011 Dec;68(6):1387-1395.
2011-11	Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter Pylori-independent gastric MALT lymphoma	Genes Chromosomes and Cancer. 2011 Nov;50(11):908-921.
2011-11	Role of chromogranin a and neuron-specific enolase biomarkers in progression-free survival (PFS) with everolimus (EVE) versus placebo (PB) in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III radiant-3 results	Neuroendocrinology. 2011 Nov;94(Suppl. 1):37.
2011-10-01	Enhancement of non-homologous end joining DNA repair capacity confers cancer cells resistance to the novel selenophene compound, D-501036	Cancer Letters. 2011 Oct 1;309(1):110-118.
2011-09	B cell-activating factor of TNF family (BAFF) signaling pathway is associated with Helicobacter Pylori-independent growth of gastric MALT lymphoma without T(11;18)(q21;q21)	European Journal of Cancer. 2011 Sep;47(Suppl 1):S648-S649.
2011-09	Phase II study of low-dose everolimus plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for first-line treatment of metastatic or recurrent gastric cancers	European Journal of Cancer. 2011 Sep;47(Suppl 1):S467.
2011-09	Nanovector-based therapies in advanced pancreatic cancer	Journal of Gastrointestinal Oncology. 2011 Sep;2(3):185-194.
2011-08-17	A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan	Cancer Chemotherapy and Pharmacology. 2011 Aug 17;67(6):1281-1289.
2011-08	Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer	Oncogene. 2011 Aug;30(33):3570-3584.
2011-07	Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan	Value in Health. 2011 Jul;14(5):647-651.
2011-05	Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001	European Journal of Cancer. 2011 May;47(8):1244-1257.
2011-05	Novel Hsp90 inhibitor NVP-AUY922 downregulates mutant c-Kit protein through transcription and enhancing protein degradation via both proteasome and autophagy-mediated pathways	Drug Metabolism Reviews. 2011 May;43(Suppl. 1):78-79.
2011-04	Activation of Akt/FoxO axis confers resistance to cisplatin in human nasopharyngeal carcinomas	Cancer Research. 2011 Apr;71:Abstract number 1701.
2011-03-07	2-Amino-3,4,5-Trimethoxybenzophenones as Potent Tubulin Polymerization Inhibitors	ChemMedChem. 2011 Mar 7;6(3):450-456.
2011-02	Loss of ASS1 expression in myxofibrosarcoma via promoter hypermethylation: Prognostic and potential therapeutic implications	Laboratory Investigation. 2011 Feb;91:17A.
2011-02	Loss of ASS1 expression in myxofibrosarcoma via promoter hypermethylation: Prognostic and potential therapeutic implications	Modern Pathology. 2011 Feb;24(Suppl. 1):17A-18A.
2011-02	Effect of inhibition of heat-shock protein 90 on mutant c-Kit protein as modulated by mRNA expression and protein degradation through both proteasome and autophagy-mediated pathways	Journal of Clinical Oncology. 2011 Feb;29(Suppl. 4):Abstract Number 54
2011-02	A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer	Journal of Clinical Oncology. 2011 Feb;29(4):Abstract Number 237.

显示项目376-400 / 510. (共21页) << < 11 12 13 14 15 16 17 18 19 20 > >> 每页显示[10|25|50]项目